E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
Jan Philipp BewersdorfMaximilian StahlJustin TaylorXiaoli MiNamrata Sonia ChandhokJustin WattsAndriy DerkachMateusz WysockiSydney X LuJessie BourcierSimon J HoggJahan RahmanSana ChaudhryTulasigeri M TotigerOmar Abdel-WahabEytan M SteinPublished in: Leukemia (2023)